No Data
Dian Diagnostics Group (300244.SZ): The laboratory in Vietnam has successfully obtained the first comprehensive independent medical laboratory practice license issued by China for overseas operations.
On December 16, Glonghui reported that Dian Diagnostics Group (300244.SZ) stated on the investor interaction platform that its lab in Vietnam successfully obtained China's first comprehensive independent medical laboratory practice license overseas, and has entered normal and stable Operation. The company will further keep pace with the nation's Belt and Road Initiative Concept and, combining its own Business advantages, focus on conducting in-depth market research in the Middle East and Southeast Asia.
Dian Diagnostics Group (300244.SZ): The company's medical diagnostic services cover the maternal and child field and can provide a variety of infant-related testing items.
On December 16, Gelonghui reported that Dian Diagnostics Group (300244.SZ) stated on the investor interaction platform that the company has dedicated services and related products for infants and children. The company's medical diagnostic services cover maternal and child health, offering various related testing projects for infants and children. Additionally, the company can provide medical institutions with the necessary equipment, reagents, consumables, and technical support services for infant and child testing business.
Even After Rising 7.4% This Past Week, Dian Diagnostics GroupLtd (SZSE:300244) Shareholders Are Still Down 55% Over the Past Three Years
Returns On Capital At Dian Diagnostics GroupLtd (SZSE:300244) Paint A Concerning Picture
dian diagnostics group (300244.SZ): The monkeypox related test kit has obtained EU CE certification
GLEH November 6th | dian diagnostics group (300244.SZ) stated on the investor interaction platform that the company's smallpox-related test kit obtained CE certification from the European Union, and the market is still being developed.
dian diagnostics group (300244.SZ): Buyback completed, cumulatively spent nearly 0.2 billion yuan to repurchase 13.88 million shares.
Delian Diagnostics Group (300244.SZ) announced that the company's share buyback period is from March 8, 2024 to October 30, 2024. The company accumulated a total of 13.88 million shares through centralized bidding trading in a buyback special securities account, accounting for 2.22% of the company's current total share capital. The highest fill price was 18.91 yuan/share, the lowest fill price was 11.64 yuan/share, and the total fill amount was 0.1995 billion yuan (excluding transaction costs). With this, the company's share buyback plan has been fully implemented.
Dian Diagnostics GroupLtd (SZSE:300244) Adds CN¥362m to Market Cap in the Past 7 Days, Though Investors From Three Years Ago Are Still Down 41%
No Data
